申请人:Hohlweg Rolf
公开号:US20090264435A1
公开(公告)日:2009-10-22
Novel aryl- and heteroarylpiperazines, use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds, and a method of treatment employing these compounds and compositions. The compounds show a high and selective binding affinity to the histamine H3 receptor indicating histamine H3 receptor antagonistic, inverse agonistic or agonistic activity. As a result, the compounds are useful for the treatment of diseases and disorders related to the histamine H3 receptor.
新型芳基和杂环基哌嗪,这些化合物的药用组合物,包含这些化合物的药用组合物,以及采用这些化合物和组合物的治疗方法。这些化合物表现出高度和选择性的结合亲和力,表明它们具有组胺H3受体拮抗、反向激动或激动活性。因此,这些化合物对于治疗与组胺H3受体相关的疾病和障碍非常有用。